SynAct Pharma
ISIN: SE0008241491 | Ticker: SYNACT | LEI: 549300RRYIEFEQ72N546
Country: Sweden
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects, so that patients can achieve immune balance and live beyond their inflammation.
AP1189, our product candidate selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression that is associated with most of the available anti-inflammatory therapies. These immunosuppressive approaches can lead to opportunistic infections and other serious side effects.
2012
Served areaWorldwide
HeadquartersMedicon Village AB Scheelevägen 2, 22381 Lund – Sweden
| Line item in (sek) | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 38,369,000.00 | N/A | 142,597,000.00 |
| Noncurrent Assets | N/A | 3,454,000.00 | N/A | 2,365,000.00 |
| Current Assets | N/A | 34,916,000.00 | N/A | 140,232,000.00 |
| Current Prepaid Expenses | N/A | 247,000.00 | N/A | 17,293,000.00 |
| Other Current Receivables | N/A | 3,107,000.00 | N/A | 6,464,000.00 |
| Current Tax Assets Current | N/A | 7,564,000.00 | N/A | 8,231,000.00 |
| Cash and cash equivalents | 14,548,000.00 | 23,997,000.00 | 23,997,000.00 | 108,245,000.00 |
| Equity And Liabilities | N/A | 38,369,000.00 | N/A | 142,597,000.00 |
| Equity | 15,868,000.00 | 20,869,000.00 | 20,869,000.00 | 126,520,000.00 |
| Issued Capital | N/A | 3,251,000.00 | N/A | 3,706,000.00 |
| Retained Earnings | N/A | -175,585,000.00 | N/A | -274,790,000.00 |
| Additional Paidin Capital | N/A | 193,602,000.00 | N/A | 394,839,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 20,869,000.00 | N/A | 126,520,000.00 |
| Noncurrent Liabilities | N/A | 2,110,000.00 | N/A | 1,064,000.00 |
| Current Liabilities | N/A | 15,390,000.00 | N/A | 15,013,000.00 |
| Trade And Other Current Payables | N/A | 4,254,000.00 | N/A | 4,723,000.00 |
| Accruals Classified As Current | N/A | 7,889,000.00 | N/A | 4,909,000.00 |
| Other Current Liabilities | N/A | 2,267,000.00 | N/A | 4,381,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Other Income | 157,000.00 | 105,000.00 |
| Profit Loss From Operating Activities | -76,699,000.00 | -105,705,000.00 |
| Finance Income | 0.00 | 58,000.00 |
| Finance Costs | 110,000.00 | 1,418,000.00 |
| Profit Loss Before Tax | -76,809,000.00 | -107,065,000.00 |
| Income Tax Expense Continuing Operations | -7,505,000.00 | -7,860,000.00 |
| Profit (loss) | -69,304,000.00 | -99,205,000.00 |
| Profit Loss Attributable To Owners Of Parent | -69,304,000.00 | -99,205,000.00 |
| Line item in (sek) | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|
| Profit (loss) | -69,304,000.00 | N/A | -99,205,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | 1,436,000.00 | N/A | 182,000.00 | N/A |
| Other Adjustments For Noncash Items | 88,000.00 | N/A | 712,000.00 | N/A |
| Interest Paid Classified As Operating Activities | 110,000.00 | N/A | 119,000.00 | N/A |
| Interest Received Classified As Operating Activities | 0.00 | N/A | 47,000.00 | N/A |
| Income Taxes Paid Refund Classified As Operating Activities | -4,625,000.00 | N/A | -7,860,000.00 | N/A |
| Cash Flows From Used In Operating Activities | -64,997,000.00 | N/A | -117,555,000.00 | N/A |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 6,000.00 | N/A | -27,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -6,000.00 | N/A | 27,000.00 | N/A |
| Proceeds From Issuing Shares | 80,000,000.00 | N/A | 228,945,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | 77,000.00 | N/A | 981,000.00 | N/A |
| Cash Flows From Used In Financing Activities | 74,323,000.00 | N/A | 200,712,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 9,319,000.00 | N/A | 83,184,000.00 | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 130,000.00 | N/A | 1,063,000.00 | N/A |
| Cash and cash equivalents | 23,997,000.00 | 14,548,000.00 | 108,245,000.00 | 23,997,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 21.03.24 | Jeppe Øvlesen | Other | Other | SEK 1,696,503.00 |
| 09.11.23 | Thomas Jonassen | Other | Other | SEK 22,072,775.00 |
| 09.11.23 | Thomas Jonass | Other | Other | SEK 13,507,656.25 |
| 16.01.23 | Jeppe Øvlesen | Other | Other | SEK 72,727,240.20 |
| 16.01.23 | James Knight | Other | Other | SEK 4,848,495.20 |
| 16.01.23 | Thomas Boesen | Other | Other | SEK 2,060,604.20 |
| 16.01.23 | Torbjörn Bjerke | Other | Other | SEK 961,223.00 |
| 16.01.23 | Jeppe Øvlesen | Other | Other | SEK 865,445.00 |
| 13.12.22 | Thomas Boesen | Other | Sell | SEK 1,250,515.60 |
| 13.12.22 | Thomas Boesen | Other | Sell | SEK 735,126.00 |
SE0008241491
LEI549300RRYIEFEQ72N546
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.